Damora Therapeutics, Inc. current report, 22 March 2024

Form 8-K Summary

Registrant: Galecto, Inc. The request metadata identifies Damora Therapeutics, Inc., but the filing names Galecto, Inc. as the registrant.

Reporting period/event date: March 22, 2024, with the report signed and filed March 26, 2024. The filing reports the transfer of the company’s common stock listing to The Nasdaq Capital Market.

Business Context and Reporting Period

This is an Item 8.01 Form 8-K concerning the company’s compliance with Nasdaq’s minimum bid-price requirement. It is not a periodic financial report and does not provide operating results for a comparable reporting period.

Financial and Other Key Metrics

  • The filing does not provide revenue, profit or loss, cash flow, margins, debt, cash balances, liquidity, or other financial statement metrics.
  • The company previously received a Nasdaq deficiency notice because its common stock had traded below the required minimum bid price of $1.00 per share for 30 consecutive business days.
  • The common stock continues to trade under the symbol GLTO.

Material Changes and Listing Status

  • On September 27, 2023, Nasdaq granted the company an initial 180-day period, through March 25, 2024, to regain compliance with the $1.00 minimum bid-price requirement.
  • The company did not regain compliance during the initial period.
  • On March 5, 2024, the company applied to transfer its securities from The Nasdaq Global Select Market to The Nasdaq Capital Market and notified Nasdaq of its intention to cure the deficiency.
  • Nasdaq approved the transfer on March 19, 2024. The securities began trading on The Nasdaq Capital Market at the opening of business on March 22, 2024.
  • Nasdaq subsequently granted an additional 180-day compliance period, reportedly through September 22, 2024. The filing text contains bracketed dates for this notification and deadline.
  • The transfer does not eliminate the bid-price deficiency or change the company’s SEC reporting obligations.

Guidance, Outlook, Risks and Contingencies

  • The company will monitor its closing bid price and may implement available measures, including a reverse stock split, if necessary.
  • If the stock closes at or above $1.00 per share for at least 10 consecutive business days during the extended period, Nasdaq is expected to provide written confirmation of compliance and close the matter.
  • If compliance is not regained by the end of the extended period, Nasdaq may issue a delisting notice. The company would then have the right to appeal to a Nasdaq hearings panel.
  • Management intends to resolve the deficiency and maintain the listing, but the filing states that there is no assurance the company will regain compliance or that any appeal would be successful.
  • Forward-looking statements are subject to risks described in the company’s Form 10-K filed March 8, 2024, and subsequent SEC filings.

Key Facts for Investor Verification

  • Verify the registrant identity, because the supplied metadata names Damora Therapeutics, Inc., while the filing names Galecto, Inc.
  • Confirm the effective Nasdaq Capital Market transfer date and the exact extended compliance deadline; the filing includes bracketed dates for the Nasdaq notification and deadline.
  • Monitor GLTO’s closing bid price and any announcement confirming compliance or initiating delisting proceedings.
  • Review any future disclosure regarding a reverse stock split, including its ratio, timing, shareholder approval requirements, and potential dilution or market effects.
  • Review the company’s March 8, 2024 Form 10-K for financial condition, liquidity, operating risks, and the full Nasdaq compliance risk discussion.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.